Related references
Note: Only part of the references are listed.Tissue remodelling in pulmonary fibrosis
Lars Knudsen et al.
CELL AND TISSUE RESEARCH (2017)
Research review on the pharmacological effects of astragaloside IV
Lei Li et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2017)
Astragaloside IV from Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4/NF-kappa B in vivo and in vitro
Xiangjun Zhou et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects
Liu-Cheng Li et al.
JOURNAL OF ETHNOPHARMACOLOGY (2017)
Inhibitory Effects of Astragaloside IV on Bleomycin-Induced Pulmonary Fibrosis in Rats Via Attenuation of Oxidative Stress and Inflammation
Wei-Na Yu et al.
INFLAMMATION (2016)
Phytomedicine polypharmacology: Cancer therapy through modulating the tumor microenvironment and oxylipin dynamics
Maria Karmella Apaya et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Paola Rogliani et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2016)
Induced Pluripotent Stem Cells Inhibit Bleomycin-Induced Pulmonary Fibrosis in Mice through Suppressing TGF-β1/Smad-Mediated Epithelial to Mesenchymal Transition
Yan Zhou et al.
FRONTIERS IN PHARMACOLOGY (2016)
Computational Modeling Predicts Simultaneous Targeting of Fibroblasts and Epithelial Cells Is Necessary for Treatment of Pulmonary Fibrosis
Hayley C. Warsinske et al.
FRONTIERS IN PHARMACOLOGY (2016)
Lung Fibroblasts, Aging, and Idiopathic Pulmonary Fibrosis
Annie Pardo et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2016)
The Role of HMGB1 in Cardiovascular Biology: Danger Signals
Jingjing Cai et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
Total glycosides of Yupingfeng protects against bleomycin-induced pulmonary fibrosis in rats associated with reduced high mobility group box 1 activation and epithelial-mesenchymal transition
Wenhui Cui et al.
INFLAMMATION RESEARCH (2015)
Total extract of Yupingfeng attenuates bleomycin-induced pulmonary fibrosis in rats
Liucheng Li et al.
PHYTOMEDICINE (2015)
MicroRNAs as potential targets for progressive pulmonary fibrosis
Subbiah Rajasekaran et al.
FRONTIERS IN PHARMACOLOGY (2015)
High-Mobility Group Box 1 Mediates Epithelial-to-Mesenchymal Transition in Pulmonary Fibrosis Involving Transforming Growth Factor-β1/Smad2/3 Signaling
Liu-Cheng Li et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Anti-Fibrotic Effects of Astragaloside IV in Systemic Sclerosis
Qing Qi et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2014)
Emerging role of HMGB1 in fibrotic diseases
Liu-Cheng Li et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2014)
Fibroblasts in fibrosis: novel roles and mediators
Ryan T. Kendall et al.
FRONTIERS IN PHARMACOLOGY (2014)
Functions of Galectin-3 and Its Role in Fibrotic Diseases
Liu-cheng Li et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p38 MAPK pathway
Xiaoming Li et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
Evidence-based treatment strategies in idiopathic pulmonary fibrosis
Juergen Behr
EUROPEAN RESPIRATORY REVIEW (2013)
Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy
L. Q. Meng et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-β1 signaling in coxsackievirus B3-induced cardiomyopathy
Ping Chen et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Study on the Relevance Between Beany Flavor and Main Bioactive Components in Radix Astragali
Haifeng Sun et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2010)
The role of high mobility group box1 in pulmonary fibrosis
Naoki Hamada et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2008)
Share Paper
